bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M

bioAffinity Technologies, Inc.

Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.
CyPath Lung revenue increased 87% YoY; tests performed up 99%, physician orders up 67%.
Net loss $14.9M vs $9.0M in 2024, driven by warrant fair value changes and higher commercialization costs.
Cash $6.5M at year-end; raised $16.9M in equity in 2025. Guidance: >100% CyPath Lung unit sales growth in 2026.
Appointed Gordon Downie MD PhD as CMO; Roberto Rios CPA and John Oppenheimer MD to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.